In predominantly CDK4-dependent cells (such as estrogen receptor-positive [ER+] breast cancer), abemaciclib, ribociclib, and palbociclib displace p21 from the CDK4/cyclin D1 complex (but not CDK6 from CDK6/cyclin D1) (20). Here, ESR1 is linked to breast cancer.